Abstract
Myocardial hypertrophy is the common endpoint of many cardiovascular stimuli such as hypertension, myocardial infarction, valvular disease, and congestive failure. Although in some ways adaptive, this hypertrophic response is pathological in that it is associated with abnormalities in both diastolic and systolic myocardial function. Moreover, the Framingham study has identified myocardial hypertrophy as an independent risk factor for cardiovascular morbidity and mortality (reviewed in [1]). However, not all forms of myocardial hypertrophy are associated with either functional abnormalities or an increase in cardiovascular mortality. This type of hypertrophy, referred to as physiologic hypertrophy, occurs with normal development and exercise training. Because these two seemingly identical phenotypes have strikingly different causes and subsequently outcomes, there has been considerable interest in the pathogenesis of myocardial hypertrophy.KeywordsCardiac MyocytesMyocardial HypertrophyAdrenergic StimulationCardiac Myocyte HypertrophyMyocyte GrowthThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
